Experience Exactech. A Great Day in the O.R.
Corporate Home Page
About Us
Exactech, Inc. is an orthopaedic company that develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. Founded in 1985 by an orthopaedic surgeon and a biomedical engineer, Exactech is committed to making every day A Great Day in the O.R. – for the surgeon, the operating room staff and above all, for the patient. It's the driving force behind everything we do. From innovative products and instrumentation, to training and education, to our supreme commitment to service… experience Exactech, a Great Day in the O.R.
Recent News
- Exactech Q3 Revenue Up 27% to $37.9M; Net Income $2.1M
- GAINESVILLE, Fla. -- October 28, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that revenue for the third quarter of 2008 increased 27% to $37.9 million from $30.0 million in the third quarter of 2007. Diluted earnings per share for the quarter were $0.16 based on net income of $2.1 million. This compares with net income of $2.5 million or $0.21 diluted EPS a year ago. As previously announced, the net income includes pre-tax legal expenses and costs of $1.2 million related to the ongoing Department of Justice inquiry.
- Exactech Updates Third Quarter Financial Guidance. Announces Q3 Earnings and Conference Call
- GAINESVILLE, Fla. -- October 14, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, said today that revenue for the quarter, which ended September 30, will be approximately $37.9 million, an increase of 26% and within the previously announced range. Earnings for the third quarter of 2008 will be below the company’s original estimates of $0.21-$0.23 diluted earnings per share and will be approximately $0.15 diluted earnings per share due to higher than expected legal expenses in the quarter of approximately $1.4 million, or $0.07 per share after taxes.
